AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03457233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natural progesterone
Description: 400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
Study NCT00603421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24 hour phone line
Description: 24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
Study NCT00603421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: Treatment as usual
Study NCT00488878 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Patients' residual tissue samples are collected
Study NCT00488878 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study NCT03303703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RENEwS
Description: The intervention participants will meet with a trained interventionist for five 60-minute sessions as a group (two groups of five participants each). In the sessions time will be divided between didactic presentation of material, active practicing of techniques, group work focused on case studies, and worksheets for further practice at home. Topics covered within the intervention include emotional awareness, balancing emotional and physical wellbeing, selecting and implementing emotion regulation strategies (such as situation selections, mindfulness, engagement/avoidance, reappraisal, and emotional sharing), and emotional monitoring.
Study NCT03112590 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-γ)
Description: Phase 1: IFN-γ 50 or 75 mcg/m\^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
Study NCT03112590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Phase 1 and Phase 2: Paclitaxel 80 mg/m\^2/week, for 12 weeks.
Study NCT03112590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
Study NCT03112590 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
Study NCT03112590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post Therapy Surgery
Description: Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
Study NCT00924417 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine Care
Description: Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
Study NCT00924417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement.
Study NCT02457585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remicade (anti tumor necrosis factor inhibitor)
Description: single arm:remicade treatment group
Study NCT04572802 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary angiography
Description: Coronary angiography was performed in patients with coronary heart disease complicated with type 2 diabetes mellitus
Study NCT01854944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1mg to 4mg
Study NCT04620707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGS based training and monitoring
Description: The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
Study NCT04620707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy as usual
Description: The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
Study NCT00323869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
Study NCT00323869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Nucleoside analog
Study NCT00323869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Alkylating agent
Study NCT01040078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5ug H1N1 Influenza vaccine
Description: 0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
Study NCT01040078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15ug H1N1 vaccine
Description: 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
Study NCT01040078 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: seasonal influenza vaccine
Description: 0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
Study NCT02037581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early detection and Integrated Care
Description: Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)
Study NCT02037581 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: Standard care as being offered by private psychiatrists
Study NCT03845374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyper-CL™ lens
Description: Use of the Hyper-CL™
Study NCT04399031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-cigarette e-liquid
Description: Participants will self-administer an experimenter-provided e-cigarette.
Study NCT00336583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin, 130 mg per square meter, on day 1
Study NCT00399672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon injections and ribavirin
Description: Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
Study NCT00399672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon injections and ribavirin
Description: Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
Study NCT03624530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor (TKIs)
Description: TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
Study NCT02732522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Study NCT02732522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal misoprostol
Study NCT04258137 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Description: Liquid biopsy will be performed at cycle 1 day 1 and cycle 2 day of each line of systemic treatment, at each tumor evaluation by Imaging and at confirmation of progression
Study NCT03249389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
Study NCT01698281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108
Description: AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity.
Study NCT01698281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCCC
Description: commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available.
Study NCT01698281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
Study NCT04048785 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Description: The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
Study NCT02097927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mango-flavour beverage
Description: The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
Study NCT01527357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrocaps
Description: Human fibrinogen and thrombin powder, for topical administration.
Study NCT01527357 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gelatin sponge
Description: Absorbable gelatin sponge for topical administration.
Study NCT01527357 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge
Description: Absorbable gelatin sponge for topical administration.
Study NCT02440412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
Study NCT02440412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rest in supine
Description: It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
Study NCT02759978 — intervention group
Intervention type: OTHER
Intervention: diagnostic workup
Description: Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.
Study NCT01076088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg
Description: Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.
Study NCT01076088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 500 mg
Description: Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
Study NCT01076088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg
Description: Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
Study NCT01076088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Sitagliptin 100 mg once daily for 24 weeks.
Study NCT01076088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets to sitagliptin or metformin for 24 weeks.
Study NCT01076088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin 850 mg
Description: Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
Study NCT01076088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Description: Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
Study NCT01259336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: Tablet 200 mg twice daily for 6 months
Study NCT01259336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment in cavitary pulmonary aspergillosis
Description: Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
Study NCT01259336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment in cavitary pulmonary aspergillosis
Description: Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
Study NCT03289195 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Biopsy
Description: Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.
Study NCT02677701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: 500mg tablet over-encapsulated to match placebo
Study NCT02677701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for azithromycin)
Study NCT02677701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled tobramycin
Description: clinically prescribed inhaled tobramycin used by subjects participating in the study
Study NCT02677701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: inhaled tobramycin
Description: clinically prescribed inhaled tobramycin used by subjects participating in the study
Study NCT02339298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music application
Description: music is applied during anaesthesia using headphones
Study NCT02339298 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: only headphones
Description: music is not applied, only headphones are placed
Study NCT02339298 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: a caudal block
Study NCT02339298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: a caudal block
Study NCT00217477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00217477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: Given IV
Study NCT01066416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Sinus Surgery
Study NCT01066416 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: medical therapy
Description: Subjects will undergo surgery 6 months after randomization
Study NCT03320629 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: apatinib S-1 radiotherapy
Description: apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT03133468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJM347
Description: Oral administration
Study NCT03320629 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: S-1 radiotherapy
Description: S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT02037919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Nexplanon Insertion
Description: Patient will have a Nexplanon inserted within 15 minutes of her abortion
Study NCT02037919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-op Nexplanon Insertion
Description: Place Nexplanon at post operative visit rather than at surgery
Study NCT00005592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90-Y-ibritumomab tiuxetan
Description: IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
Study NCT00005592 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
Study NCT00005592 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: indium In 111 ibritumomab tiuxetan
Description: IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
Study NCT03323307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT imaging
Description: imaging of retina using OCT device
Study NCT02887846 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated Humidified High-Flow Nasal Cannula
Description: Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 \< 0,40, Pa CO2 \< 65 mmHg, pH> 7.20, MAP (mean airway pressure) \<7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is\<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 \< 0.30 at 24 hours and above, free oxygen will be introduced.
Study NCT03245788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lay Navigation
Description: Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
Study NCT03700892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde e-liquid
Description: Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
Study NCT03700892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PG/VG e-liquid
Description: Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
Study NCT02955186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saracatinib
Description: Saracatinib 125 mg once per day for 8 days
Study NCT02955186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo once per day for 8 days
Study NCT04646317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine injection
Description: Infusion of dexmedetomidine will be prepared in Four syringes of 50ml containing dexmedetomidine in concentration of 1 microgram per millilitre.
Study NCT03133468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study NCT04646317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% as placebo
Study NCT03045484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Description: CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
Study NCT00780442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg DCS
Study NCT00780442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo